[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020001875A - Forma polimorfica de tg02. - Google Patents

Forma polimorfica de tg02.

Info

Publication number
MX2020001875A
MX2020001875A MX2020001875A MX2020001875A MX2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A
Authority
MX
Mexico
Prior art keywords
acid addition
addition salts
free base
polymorphic forms
crystalline polymorphic
Prior art date
Application number
MX2020001875A
Other languages
English (en)
Inventor
Tracy Parrott
Robert K Mansfield
Original Assignee
Tragara Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tragara Pharmaceuticals Inc filed Critical Tragara Pharmaceuticals Inc
Publication of MX2020001875A publication Critical patent/MX2020001875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona formas polimórficas cristalinas de base libre de TG02 y sales de adición de ácido de TG02, composiciones farmacéuticas que comprenden formas polimórficas cristalinas de base libre de TG02 y sales de adición de ácido de TG02, y métodos para tratar cáncer y otras enfermedades en un paciente con formas polimórficas cristalinas de base libre de TG02 y sales de adición de ácido de TG02.
MX2020001875A 2017-08-18 2018-08-17 Forma polimorfica de tg02. MX2020001875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762547157P 2017-08-18 2017-08-18
PCT/US2018/000264 WO2019035985A1 (en) 2017-08-18 2018-08-17 POLYMORPHIC FORM OF TG02

Publications (1)

Publication Number Publication Date
MX2020001875A true MX2020001875A (es) 2020-07-29

Family

ID=65359869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001875A MX2020001875A (es) 2017-08-18 2018-08-17 Forma polimorfica de tg02.

Country Status (14)

Country Link
US (4) US10544162B2 (es)
EP (2) EP4364741A3 (es)
JP (1) JP7250764B2 (es)
KR (1) KR102758037B1 (es)
CN (1) CN111372934B (es)
AU (1) AU2018317865B2 (es)
CA (1) CA3073270A1 (es)
ES (1) ES2977589T3 (es)
IL (1) IL272697B2 (es)
MX (1) MX2020001875A (es)
RU (1) RU2020111019A (es)
SG (1) SG11202001441WA (es)
TW (1) TWI785098B (es)
WO (1) WO2019035985A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195603B (zh) 2016-03-24 2022-11-08 科瑞华生物技术有限公司 用tg02治疗癌症
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型
WO2020219606A1 (en) * 2019-04-22 2020-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of erk5 inhibitors for treating gliomas in pediatric subjects
CN110664760B (zh) * 2019-10-28 2020-10-23 浙江大学 一种负载vegfr靶向抑制剂的药物载体及其制备方法和应用
WO2024031406A1 (en) * 2022-08-10 2024-02-15 Xiang Li Idh mutations as biomarkers for zotiraciclib therapy
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用
CN115305251B (zh) * 2022-08-30 2023-06-27 中国农业科学院北京畜牧兽医研究所 Ap2-mybl2分子模块在调控原花色素生物合成中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
NZ517955A (en) 1999-08-23 2004-03-26 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 for modulating the immune response
CA2381770C (en) 1999-08-24 2007-08-07 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2003213054A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
BRPI0607809A2 (pt) * 2005-02-18 2009-06-13 Abraxis Bioscience Inc uso de uma composição compreendendo nanopartìculas, composição e kit
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101513492B1 (ko) 2005-11-16 2015-04-20 에스*바이오 피티이 리미티드 헤테로알킬이 결합된 피리미딘 유도체
MY162157A (en) 2007-04-16 2017-05-31 Abbott Lab Substituted indole mcl-1 inhibitors
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
EP2418955A4 (en) * 2009-04-15 2012-11-21 Poniard Pharmaceuticals Inc ORBIOTIC ANTICANCER THERAPY BASED ON HIGH BIODISIBILITY PICOPLATIN
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
EA027622B1 (ru) * 2010-02-05 2017-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Твердофазные формы макроциклических ингибиторов киназы
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US9801853B2 (en) 2010-04-06 2017-10-31 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
RU2014117632A (ru) 2011-09-30 2015-11-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы лечения злокачественной опухоли
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
CA3177515A1 (en) 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3698809A1 (en) 2012-07-31 2020-08-26 The Brigham & Women's Hospital, Inc. Modulation of the immune response using agents binding tim-3 and ceacam-1
MX376008B (es) 2012-10-15 2025-03-07 Epizyme Inc Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
SG11201505680RA (en) 2013-02-21 2015-09-29 Pfizer Solid forms of a selective cdk4/6 inhibitor
HUE049957T2 (hu) 2013-03-15 2020-11-30 Glaxosmithkline Ip Dev Ltd Lag-3 elleni kötõfehérjék
BR112016005303A2 (pt) 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
CN113583129A (zh) 2014-03-14 2021-11-02 诺华股份有限公司 针对lag-3的抗体分子及其用途
CN109195603B (zh) 2016-03-24 2022-11-08 科瑞华生物技术有限公司 用tg02治疗癌症
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型

Also Published As

Publication number Publication date
IL272697A (en) 2020-04-30
TW201920199A (zh) 2019-06-01
IL272697B2 (en) 2023-12-01
US20190055263A1 (en) 2019-02-21
WO2019035985A1 (en) 2019-02-21
US12043630B2 (en) 2024-07-23
SG11202001441WA (en) 2020-03-30
US20200262843A1 (en) 2020-08-20
JP7250764B2 (ja) 2023-04-03
US10544162B2 (en) 2020-01-28
US20240254141A1 (en) 2024-08-01
RU2020111019A3 (es) 2022-03-18
CN111372934A (zh) 2020-07-03
CA3073270A1 (en) 2019-02-21
AU2018317865B2 (en) 2023-03-16
EP4364741A3 (en) 2024-07-03
JP2020531463A (ja) 2020-11-05
EP3668876A4 (en) 2021-04-28
RU2020111019A (ru) 2021-09-20
KR20200078481A (ko) 2020-07-01
EP3668876B1 (en) 2024-01-24
IL272697B1 (en) 2023-08-01
EP3668876A1 (en) 2020-06-24
CN111372934B (zh) 2024-04-26
TWI785098B (zh) 2022-12-01
EP4364741A2 (en) 2024-05-08
KR102758037B1 (ko) 2025-01-22
AU2018317865A1 (en) 2020-03-19
US20240254142A1 (en) 2024-08-01
ES2977589T3 (es) 2024-08-27

Similar Documents

Publication Publication Date Title
MX2020001875A (es) Forma polimorfica de tg02.
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
PH12018501237A1 (en) Isoindole compounds
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX369506B (es) Composiciones de sales metálicas.
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
NZ726132A (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.